Allogene officer plans sale of 29,697 shares

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. (ALLO) is the issuer of common stock for which Douglas Earl Martin, an officer, has filed a notice under Rule 144 to sell up to 29,697 shares of common stock through Morgan Stanley Smith Barney LLC on or after 08/21/2026, with an aggregate market value of $62,957.64. The shares relate to a restricted stock unit award, with 81,719 shares vesting on 08/20/2026 as part of the issuer's equity compensation plan.

Key Figures

Common shares to be sold under Rule 144: 29,697 shares Aggregate market value of shares to be sold: $62,957.64 CUSIP: 345490881 +3 more

6 metrics

Common shares to be sold under Rule 144 29,697 shares Planned sale of Allogene Therapeutics, Inc. common stock through Morgan Stanley Smith Barney LLC

Aggregate market value of shares to be sold $62,957.64 Value associated with 29,697 shares of Allogene Therapeutics, Inc. common stock

CUSIP 345490881 Identifier associated with Allogene Therapeutics, Inc. common stock in the notice

RSU shares vesting 81,719 shares Restricted stock unit award vesting on 08/20/2026 as part of equity compensation plan

RSU vesting date 08/20/2026 Vesting date of restricted stock unit award related to the common stock

Planned sale date 08/21/2026 Date listed for the potential sale of 29,697 common shares on NASDAQ

Key Terms

Rule 144, restricted stock unit, equity compensation plan

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock unit financial

"Vesting of restricted stock unit award | Allogene Therapeutics, Inc"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing indicate for Allogene Therapeutics, Inc. (ALLO)?

It indicates that officer Douglas Earl Martin has given notice under Rule 144 of his intent to sell up to 29,697 shares of Allogene Therapeutics, Inc. common stock through Morgan Stanley Smith Barney LLC.

How many ALLO shares are covered by Douglas Earl Martin’s planned Rule 144 sale?

The planned Rule 144 sale covers up to 29,697 shares of Allogene Therapeutics, Inc. common stock, with an indicated aggregate market value of $62,957.64 as provided in the notice.

What is the planned sale date for the ALLO shares under this Form 144?

The notice lists a planned sale date of 08/21/2026 for up to 29,697 Allogene Therapeutics, Inc. common shares to be sold on NASDAQ through Morgan Stanley Smith Barney LLC.

What is the source of the ALLO shares to be sold by Douglas Earl Martin?

The notice states that the common stock relates to a restricted stock unit award, with 81,719 shares vesting on 08/20/2026, granted as part of Allogene Therapeutics, Inc.’s equity compensation plan.

Which broker is handling the potential Rule 144 sale of ALLO shares?

The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, which is listed as handling the potential sale of Allogene Therapeutics, Inc. common stock on NASDAQ.

Does Allogene Therapeutics, Inc. receive proceeds from this planned Rule 144 sale?

The notice describes a planned sale of existing common shares for the account of Douglas Earl Martin. It identifies the issuer and the selling person but does not describe any proceeds as being received by Allogene Therapeutics, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 07:27 PM Accepted by SEC EDGAR 08/21/2026 - 07:26 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001362155
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Allogene Therapeutics, Inc.
SEC File Number	001-38693
Address of Issuer	210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	(650) 457-2700
Name of Person for Whose Account the Securities are To Be Sold	Douglas Earl Martin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	29697	62957.64	345490881	08/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/20/2026	Vesting of restricted stock unit award	Allogene Therapeutics, Inc			81719	08/20/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Douglas Earl Martin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)